Polygenic modulation of lipoprotein(a)-associated cardiovascular risk
Mark Trinder, View ORCID ProfileLiam R. Brunham
doi: https://doi.org/10.1101/2020.02.22.20026757
Mark Trinder
aCentre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada
bExperimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada
MScLiam R. Brunham
aCentre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada
bExperimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada
cDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
dDepartment of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
MD, PhDArticle usage
Posted February 25, 2020.
Polygenic modulation of lipoprotein(a)-associated cardiovascular risk
Mark Trinder, Liam R. Brunham
medRxiv 2020.02.22.20026757; doi: https://doi.org/10.1101/2020.02.22.20026757
Subject Area
Subject Areas
- Addiction Medicine (404)
- Allergy and Immunology (713)
- Anesthesia (208)
- Cardiovascular Medicine (2978)
- Dermatology (254)
- Emergency Medicine (446)
- Epidemiology (12836)
- Forensic Medicine (12)
- Gastroenterology (836)
- Genetic and Genomic Medicine (4636)
- Geriatric Medicine (426)
- Health Economics (733)
- Health Informatics (2952)
- Health Policy (1075)
- Hematology (394)
- HIV/AIDS (936)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (478)
- Neurology (4430)
- Nursing (238)
- Nutrition (653)
- Oncology (2303)
- Ophthalmology (654)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (284)
- Palliative Medicine (85)
- Pathology (503)
- Pediatrics (1201)
- Primary Care Research (506)
- Public and Global Health (7024)
- Radiology and Imaging (1556)
- Respiratory Medicine (924)
- Rheumatology (447)
- Sports Medicine (386)
- Surgery (493)
- Toxicology (60)
- Transplantation (213)
- Urology (185)